Impact Factor
3.72
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.05
1,939 total citations
h5-index
65
h5 depth signal
Cited share
52.6%
266 of 506
Total citations
1,939
Citation footprint
Metric signal
2.79
External metric anchor
Self-citation
0.7%
14 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
2,562
China
327
Germany
262
United Kingdom
231
Canada
194
Citing Fields of Research
Immunology
4,160
Immunotherapy
1,370
Oncology
760
Breast Cancer
246
Cancer, Autophagy & Apoptosis
209
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
5,022
Articles tracked across the journal lifetime
Indexed publication set
506
266 cited publications
Last 12 months
392
32.7 publications/month
Open access share
20.7%
81 OA publications in the last year
Leading citing country
United States
2,562 citing publications
Leading citing field
Immunology
4,160 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v1n1, July 2013-
v1n1, July 2013- ; selected citations only before this date
Research Focus & Classification
Indexed Subjects
Immunology
Issuing & Sponsoring Bodies
issuing body
American Association for Cancer Research
Broad Categories
Allergy and Immunology
Neoplasms
Immunology
MeSH Descriptors
Immune System Phenomena
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1158/2326-6066.cir-26-0305
Open DOI
Malignant Ascites Harbors Immune Niche with IL-10 Enriched Effector Dysfunction and Persistent Cancer-Binding IgG
Malignant ascites provides a window into cancer-immune interactions in the peritoneal cavity. Using Cytometry by Time of Flight (CyTOF), we analyzed ascitic immune cells collected from patients with advanced gastrointestinal cancers, non...
02
DOI 10.1158/2326-6066.cir-26-0608
Open DOI
Disruption of the CRL5 ubiquitin ligase complex enhances engineered T-cell persistence under chronic tumor antigen exposure
Engineered T-cell therapies are limited by progressive dysfunction under chronic tumor antigen exposure, and genetic perturbation of negative regulators has emerged as a promising strategy to sustain effector activity. We reanalyzed a ge...
03
DOI 10.1158/2326-6066.cir-26-0181
Open DOI
Cullin-5 RING E3 ligase limits CD8⁺ T-cell persistence and effector responses during chronic antigen stimulation
T-cell exhaustion limits durable antitumor responses and remains a barrier to adoptive cell therapies (ACT) in solid tumors. To identify regulators of T-cell persistence, we performed genome-wide CRISPR knockout screens in primary human ...
04
DOI 10.1158/2326-6066.cir-26-0770
Open DOI
Targeting CCR1/CCR2 attenuates cytokine release syndrome while preserving CAR T-cell antitumor activity
Cytokine release syndrome (CRS) is a major dose-limiting toxicity of chimeric antigen receptor (CAR) T-cell therapy, yet the upstream mechanisms driving macrophage activation remain incompletely understood. Here, we established a xenogra...
05
DOI 10.1158/2326-6066.cir-26-0104
Open DOI
A High Density of Impaired Tertiary Lymphoid Structures Is Associated with Higher Tumor Stage and Recurrence in Non–Muscle-Invasive Bladder Cancer
Tertiary lymphoid structures (TLS) have emerged as critical immune niches within the tumor microenvironment across various cancers. However, their structural organization and functional roles in non–muscle-invasive bladder cancer (NMIBC)...
06
DOI 10.1158/2326-6066.cir-26-0706
Open DOI
Addition of chemotherapy to radiotherapy promotes progenitor-exhausted CD8⁺ T-cell clonal dominance in head and neck cancer
Concomitant chemoradiotherapy (CRT) is a standard-of-care treatment for unresectable locally advanced head and neck squamous cell carcinoma (LA-SCCHN), but its immune effects, particularly relative to radiotherapy (RT) alone, remain inco...
07
DOI 10.1158/2326-6066.cir-26-0367
Open DOI
TCR sensitivity shapes recognition of tumor antigen presented by host cells and TCR-T cell efficacy in solid tumors
Despite advances in adoptive T cell therapy, therapeutic efficacy in solid tumors remains inconsistent, and the mechanistic determinants of treatment failure are incompletely understood. Increasing evidence suggests that effective antitu...
08
DOI 10.1158/2326-6066.cir-26-0177
Open DOI
Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Immune checkpoint blockade (ICB) has markedly improved overall survival in various cancers but is associated with severe and sometimes fatal immune-related adverse events (irAE). Current management of irAEs involves discontinuation of IC...
09
DOI 10.1158/2326-6066.cir-26-0472
Open DOI
The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
The tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is characterized by the restrained function of effector T cells that drive resistance to immunotherapy. Although tumor-extrinsic stroma and myeloid cells have be...
10
DOI 10.1158/2326-6066.cir-25-1589
Open DOI
Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome
T-cell immune tolerance is established in part through the activity of the autoimmune regulator (AIRE) transcription factor in medullary thymic epithelial cells (mTEC) of the thymus. AIRE induces expression of peripheral tissue–specific ...
Bibliographical & Catalog Notes
Print issues ceased with v. 8, no. 12 (Dec. 2020).
Also issued online.